- CEO:Peter Crock
When it comes to the medicinal cannabis market, the Cann Group (ASX:CAN) are dedicated to breaking through the grass ceiling. The company's goal is to become the leading developer and supplier of cannabis, cannabis resin, and medicinal cannabis products in Australia.
Rather than trying to fill a specific niche like some of its competing cannabis stocks—such as targeted clinical applications or over-the-counter skincare products—Cann's team is focused on refining, supplying, and distributing cannabis.
The company favours a vertically integrated business model that handles all aspects of the cannabis market, covering everything from cultivation, clinical evaluation, and research and development, all the way down to packaging and exports.
The Cann Group was also granted the first ever Australian Medicinal Cannabis Research Licence in February 2017, and it is currently building the largest cultivation facility in the country, located in close proximity to Melbourne Airport. The state-of-the-art facility will to be over 37,000 square metres in size, with Australia Pacific Airports Melbourne contributing $100 million to the project via an unquantified lease incentive.
Cann has also secured strategic partnerships with a number of other international companies, including the Canadian marijuana giant Aurora Cannabis, the Canopy Growth Corp, and Fundacion Daya.
Stay updated about
Signup to get updates.